Clinical Trials Browser

Meningeal Carcinomatosis × Pemetrexed × Clear all

NCT06462222 2026-05-11

Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors

Phase 1/2 Active not recruiting

Meningeal Carcinomatosis

NCT06431685 2026-05-08

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

Phase 1 Recruiting

Meningeal Carcinomatosis

NCT06812871 2026-04-02

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Phase 2 Completed

Meningeal Carcinomatosis

NCT05805631 2026-03-24

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06663306 2026-03-02

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT06296745 2026-01-30

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06304441 2025-09-29

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Phase NA Recruiting

Meningeal Carcinomatosis

NCT06462092 2025-09-29

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms, Meningeal Carcinomatosis

NCT06762080 2025-05-20

Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis

Phase 1/2 Recruiting

Meningeal Carcinomatosis

NCT06809517 2025-05-20

Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis

Phase 1/2 Recruiting

Meningeal Carcinomatosis

NCT06809530 2025-05-18

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

Phase 1/2 Recruiting

Meningeal Carcinomatosis

NCT05289908 2025-05-04

Intrathecal Pemetrexed for Leptomeningeal Metastasis

Phase 1/2 Completed

Meningeal Carcinomatosis

NCT06643000 2025-03-06

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Phase NA Recruiting

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06861218 2025-03-06

Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases

Phase 2 Not yet recruiting

Meningeal Carcinomatosis

NCT06399926 2024-05-06

Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir

Lung Neoplasms, Meningeal Carcinomatosis

NCT05810350 2023-04-13

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT05305885 2022-09-30

Intra-pemetrexed Alone or Combined With Concurrent Radiotherapy for Leptomeningeal Metastasis

Phase NA Unknown

Meningeal Carcinomatosis

NCT00424242 2021-09-08

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

Phase EARLY_PHASE1 Completed

CNSDermatologicLymphoidMyeloidOther hematologic neoplasmOther neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Immunoglobulin Light-chain Amyloidosis, Blast Crisis, Brain Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Polycythemia Vera, Precancerous Conditions, Sezary Syndrome, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Central Nervous System Neoplasms, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis, Meningeal Carcinomatosis, Intraocular Lymphoma

NCT03507244 2019-12-26

Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors

Phase 1/2 Completed

Meningeal Carcinomatosis

NCT03101579 2019-03-19

Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer

Phase 1 Completed

Recurrence, Meningeal Carcinomatosis